Recent Updates
Recently added Catalysts

Low-Grade Serous Ovarian Carcinoma: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$723Muniverse median $1.20B
Allocated capital$90M$723M competing
Phase 3 or filed10 mid, 0 early
Pure plays0this indication only
Capital rank276/299crowding rank 276

Low-Grade Serous Ovarian Carcinoma is uncontested. Verastem (VSTM) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Avutometinib in phase 3.

There is no public comparable to price it against. VSTM spreads its $723M market cap across 8 indications, so $90M of it is allocated here.

The one programme here is in late-stage development, with 1 dated catalyst in the next 12 months.

$90M of allocated capital sits in Low-Grade Serous Ovarian Carcinoma, ranking it 276th of 299 indications by the money committed to it.

Companies developing drugs for Low-Grade Serous Ovarian Carcinoma 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
VSTMVerastemAvutometinibPhase 36$723MNo8 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Low-Grade Serous Ovarian Carcinoma counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Low-Grade Serous Ovarian Carcinoma has one competitor and a median of $723M.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Endometrioid Carcinoma1 company · $90M · median $723MUncontestedB-Cell Acute Lymphoblastic Leukemia2 companies · $92M · median $221MOrphan cornerHigh-grade Serous Ovarian Cancer1 company · $98M · median $295MUncontestedAdenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma1 company · $64M · median $129MUncontestedRelapsed/Refractory Non-Hodgkin's Lymphoma1 company · $117M · median $351MUncontestedWell-differentiated Pancreatic Neuroendocrine Tumor1 company · $119M · median $356MUncontestedRecurrent Cutaneous T-Cell Lymphoma1 company · $119M · median $356MUncontestedMetastatic Urothelial Cancer1 company · $54M · median $214MUncontested

Low-Grade Serous Ovarian Carcinoma pipeline questions

Which biotech companies are developing drugs for Low-Grade Serous Ovarian Carcinoma?

Verastem (VSTM, Avutometinib, Phase 3). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Low-Grade Serous Ovarian Carcinoma.

How advanced is the Low-Grade Serous Ovarian Carcinoma pipeline?

Of the 1 clinical-stage programme in Low-Grade Serous Ovarian Carcinoma, 1 is in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Low-Grade Serous Ovarian Carcinoma?

No. VSTM is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Low-Grade Serous Ovarian Carcinoma, which is why the indication is classified as uncontested.

When is the next Low-Grade Serous Ovarian Carcinoma catalyst?

The next dated catalyst in Low-Grade Serous Ovarian Carcinoma is VSTM on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map